

Konstantinos Kostikas,, Fccp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7551441/publications.pdf>

Version: 2024-02-01

253
papers

6,452
citations

66234

42
h-index

88477

70
g-index

256
all docs

256
docs citations

256
times ranked

8259
citing authors

#	ARTICLE	IF	CITATIONS
1	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. <i>European Respiratory Journal</i> , 2017, 49, 1600965.	3.1	432
2	pH in Expired Breath Condensate of Patients with Inflammatory Airway Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1364-1370.	2.5	391
3	Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function. <i>Inhalation Toxicology</i> , 2013, 25, 91-101.	0.8	332
4	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 329-339.	2.5	196
5	Oxidative Stress in Expired Breath Condensate of Patients With COPD. <i>Chest</i> , 2003, 124, 1373-1380.	0.4	167
6	Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits. <i>European Respiratory Journal</i> , 2017, 49, 1602129.	3.1	156
7	Toward clinically applicable biomarkers for asthma: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1835-1851.	2.7	135
8	Leukotriene B ₄ in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma. <i>Chest</i> , 2005, 127, 1553-1559.	0.4	120
9	LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. <i>International Journal of COPD</i> , 2017, Volume 12, 907-922.	0.9	109
10	Clinical implications for Vascular Endothelial Growth Factor in the lung: friend or foe?. <i>Respiratory Research</i> , 2006, 7, 128.	1.4	102
11	VEGF, TNF- α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. <i>Lung Cancer</i> , 2009, 64, 219-225.	0.9	86
12	Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. <i>Lung Cancer</i> , 2004, 44, 183-191.	0.9	82
13	Plasma leptin and adiponectin in COPD exacerbations: Associations with inflammatory biomarkers. <i>Respiratory Medicine</i> , 2010, 104, 40-46.	1.3	78
14	Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 26-31.	1.1	76
15	Serum uric acid as a predictor of mortality and future exacerbations of COPD. <i>European Respiratory Journal</i> , 2014, 43, 43-53.	3.1	74
16	Nasal continuous positive airway pressure treatment reduces systemic oxidative stress in patients with severe obstructive sleep apnea syndrome. <i>Sleep Medicine</i> , 2009, 10, 87-94.	0.8	72
17	Biomarkers in the Exhaled Breath Condensate of Healthy Adults: Mapping the Path Towards Reference Values. <i>Current Medicinal Chemistry</i> , 2008, 15, 620-630.	1.2	69
18	Matrix Metalloproteinases in Respiratory Diseases: From Pathogenesis to Potential Clinical Implications. <i>Current Medicinal Chemistry</i> , 2009, 16, 1214-1228.	1.2	68

#	ARTICLE	IF	CITATIONS
19	How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 139-149.	2.5	68
20	The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. European Respiratory Journal, 2013, 41, 815-823.	3.1	67
21	Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respiratory Medicine, 2009, 103, 919-926.	1.3	65
22	Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1761-1767.	2.7	65
23	Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respiratory Medicine, 2010, 104, 275-282.	1.3	63
24	Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulmonary Medicine, 2009, 9, 18.	0.8	62
25	Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. Current Drug Targets, 2018, 19, 1882-1896.	1.0	60
26	Statins and outcome after hospitalization for COPD exacerbation: A prospective study. Pulmonary Pharmacology and Therapeutics, 2011, 24, 625-631.	1.1	59
27	Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. Chest, 2017, 151, 47-59.	0.4	59
28	Techniques for assessing small airways function: Possible applications in asthma and COPD. Respiratory Medicine, 2016, 119, e2-e9.	1.3	57
29	Systemic Biomarkers in Exacerbations of COPD. Chest, 2012, 141, 396-405.	0.4	54
30	One-year non-invasive ventilation in chronic hypercapnic COPD: Effect on quality of life. Respiratory Medicine, 2008, 102, 904-911.	1.3	53
31	Portable Exhaled Nitric Oxide as a Screening Tool for Asthma in Young Adults During Pollen Season. Chest, 2008, 133, 906-913.	0.4	52
32	Oxidative stress in patients with obstructive sleep apnea syndrome. Sleep and Breathing, 2013, 17, 549-555.	0.9	52
33	The role of macrophages in obstructive airways disease: Chronic obstructive pulmonary disease and asthma. Cytokine, 2013, 64, 613-625.	1.4	52
34	Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research, 2017, 18, 140.	1.4	52
35	Leptin, Adiponectin, and Ghrelin Levels in Female Patients with Asthma during Stable and Exacerbation Periods. Journal of Asthma, 2013, 50, 188-197.	0.9	50
36	Acute phase markers for the differentiation of infectious and malignant pleural effusions. Respiratory Medicine, 2007, 101, 910-918.	1.3	49

#	ARTICLE	IF	CITATIONS
37	Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. <i>European Journal of Internal Medicine</i> , 2011, 22, 103-107.	1.0	47
38	Oxidative Stress in Patients with COPD. <i>Current Drug Targets</i> , 2011, 12, 469-477.	1.0	47
39	Global assessment of the COPD patient: Time to look beyond FEV1?. <i>Respiratory Medicine</i> , 2009, 103, 650-660.	1.3	46
40	Pulmonary biomarkers in COPD exacerbations: a systematic review. <i>Respiratory Research</i> , 2013, 14, 111.	1.4	46
41	Artificial intelligence techniques in asthma: a systematic review and critical appraisal of the existing literature. <i>European Respiratory Journal</i> , 2020, 56, 2000521.	3.1	46
42	Identification and treatment of T2-low asthma in the era of biologics. <i>ERJ Open Research</i> , 2021, 7, 00309-2020.	1.1	44
43	Mitochondrial genetic background plays a role in increasing risk to asthma. <i>Molecular Biology Reports</i> , 2012, 39, 4697-4708.	1.0	43
44	Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype. <i>Respiratory Medicine</i> , 2015, 109, 1404-1409.	1.3	43
45	Control of asthma in real life: still a valuable goal?. <i>European Respiratory Review</i> , 2015, 24, 361-369.	3.0	43
46	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. <i>Chest</i> , 2018, 154, 798-807.	0.4	42
47	The Association of Metabolic Syndrome with Adipose Tissue Hormones and Insulin Resistance in Patients with COPD without Co-morbidities. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 414-420.	0.7	41
48	The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. <i>International Journal of COPD</i> , 2017, Volume 12, 1325-1337.	0.9	40
49	Exhaled NO and exhaled breath condensate pH in the evaluation of asthma control. <i>Respiratory Medicine</i> , 2011, 105, 526-532.	1.3	39
50	Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 33.	1.1	38
51	Noninvasive Ventilation in Chronic Respiratory Failure: Effects on Quality of Life. <i>Respiration</i> , 2011, 81, 402-410.	1.2	37
52	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , 2016, 47, 1635-1644.	3.1	37
53	Patients' perspectives on COPD: findings from a social media listening study. <i>ERJ Open Research</i> , 2019, 5, 00128-2018.	1.1	37
54	Effects of hypoxia on diaphragmatic fatigue in highly trained athletes. <i>Journal of Physiology</i> , 2007, 581, 299-308.	1.3	36

#	ARTICLE	IF	CITATIONS
55	Increased Levels of Osteopontin in Sputum Supernatant in Patients With COPD. <i>Chest</i> , 2014, 146, 951-958.	0.4	36
56	Prevalence of sleep-related symptoms in a primary care population – their relation to asthma and COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2007, 16, 222-228.	2.5	35
57	Association of TLR4-T399I Polymorphism with Chronic Obstructive Pulmonary Disease in Smokers. <i>Clinical and Developmental Immunology</i> , 2009, 2009, 1-6.	3.3	35
58	Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 375-381.	0.7	35
59	Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. <i>Respiratory Research</i> , 2019, 20, 178.	1.4	34
60	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. <i>European Respiratory Journal</i> , 2022, 59, 2102006.	3.1	34
61	Increased Oxidative Stress in Exudative Pleural Effusions. <i>Chest</i> , 2005, 128, 3291-3297.	0.4	33
62	<p>Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 995-1008.	0.9	33
63	Prevalence of chronic diseases and morbidity in primary health care in central Greece: An epidemiological study. <i>BMC Health Services Research</i> , 2010, 10, 252.	0.9	32
64	Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers. <i>Respiratory Research</i> , 2011, 12, 67.	1.4	32
65	Effective sleep apnoea treatment improves cardiac function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 157-162.	0.8	32
66	Therapy with protonâpump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. <i>Respirology</i> , 2016, 21, 883-890.	1.3	32
67	Combined pulmonary fibrosis and emphysema: The many aspects of a cohabitation contract. <i>Respiratory Medicine</i> , 2016, 117, 14-26.	1.3	32
68	Prevalence and determinants of current and secondhand smoking in Greece: results from the Global Adult Tobacco Survey (GATS) study. <i>BMJ Open</i> , 2017, 7, e013150.	0.8	32
69	Increased levels of osteopontin in sputum supernatant of smoking asthmatics. <i>Cytokine</i> , 2013, 61, 251-255.	1.4	30
70	The asthma–COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?. <i>International Journal of COPD</i> , 2016, 11, 1297.	0.9	29
71	Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. <i>International Journal of COPD</i> , 2018, Volume 13, 2557-2568.	0.9	29
72	Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. <i>Respiratory Research</i> , 2018, 19, 121.	1.4	29

#	ARTICLE	IF	CITATIONS
73	Overnight Changes in the Cerebral Vascular Response to Isocapnic Hypoxia and Hypercapnia in Healthy Humans. <i>Stroke</i> , 2005, 36, 2367-2372.	1.0	28
74	Associations between BODE Index and Systemic Inflammatory Biomarkers in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 408-413.	0.7	28
75	Biomarkers Obtained by Non-Invasive Methods in Patients with COPD: Where do we Stand, what do we Expect?. <i>Current Medicinal Chemistry</i> , 2009, 16, 2824-2838.	1.2	27
76	Fetuin-A is Associated with Disease Severity and Exacerbation Frequency in Patients with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 28-34.	0.7	27
77	Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 38.	1.1	27
78	Serum levels of hyaluronic acid are associated with COPD severity and predict survival. <i>European Respiratory Journal</i> , 2019, 53, 1801183.	3.1	27
79	Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?. <i>Current Drug Targets</i> , 2013, 14, 177-191.	1.0	26
80	The Epidemiology of Pulmonary Nontuberculous Mycobacteria: Data from a General Hospital in Athens, Greece, 2007-2013. <i>Pulmonary Medicine</i> , 2014, 2014, 1-9.	0.5	25
81	Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 730-738.	2.5	25
82	Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1223-1226.	2.5	25
83	The role of endosomal toll-like receptors in asthma. <i>European Journal of Pharmacology</i> , 2017, 808, 14-20.	1.7	24
84	One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β_2 -agonist in UK primary care settings. <i>Respiratory Medicine</i> , 2020, 162, 105859.	1.3	24
85	Vascular endothelial growth factor and cysteinyl leukotrienes in sputum supernatant of patients with asthma. <i>Respiratory Medicine</i> , 2013, 107, 1339-1345.	1.3	23
86	Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial. <i>Respirology</i> , 2018, 23, 1152-1159.	1.3	23
87	Validation of the portable Bluetooth® Air Next spirometer in patients with different respiratory diseases. <i>Respiratory Research</i> , 2020, 21, 79.	1.4	22
88	Can We Delay the Accelerated Lung Aging in COPD? Anti-Aging Molecules and Interventions. <i>Current Drug Targets</i> , 2013, 14, 149-157.	1.0	22
89	Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. <i>Respirology</i> , 2021, 26, 1027-1040.	1.3	22
90	The determinants of therapeutic levels of continuous positive airway pressure in elderly sleep apnea patients. <i>Respiratory Medicine</i> , 2006, 100, 1216-1225.	1.3	21

#	ARTICLE	IF	CITATIONS
91	Secondhand smoke exposure induces acutely airway acidification and oxidative stress. <i>Respiratory Medicine</i> , 2013, 107, 172-179.	1.3	21
92	Adrenomedullin optimises mortality prediction in COPD patients. <i>Respiratory Medicine</i> , 2015, 109, 734-742.	1.3	20
93	<p>Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 853-861.	0.9	20
94	Comparison of a network of primary care physicians and an open spirometry programme for COPD diagnosis. <i>Respiratory Medicine</i> , 2011, 105, 274-281.	1.3	19
95	Differences in COPD Exacerbation Risk Between Women and Men. <i>Chest</i> , 2019, 156, 674-684.	0.4	19
96	Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?. <i>European Respiratory Journal</i> , 2015, 46, 846-849.	3.1	18
97	Treatment response in COPD: does FEV₁ say it all? A <i>post hoc</i> analysis of the CRYSTAL study. <i>ERJ Open Research</i> , 2019, 5, 00243-2018.	1.1	18
98	<p>Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1789-1800.	0.9	17
99	Effects of exercise-induced arterial hypoxaemia and work rate on diaphragmatic fatigue in highly trained endurance athletes. <i>Journal of Physiology</i> , 2006, 572, 539-549.	1.3	16
100	Body Composition in Severe Refractory Asthma: Comparison with COPD Patients and Healthy Smokers. <i>PLoS ONE</i> , 2010, 5, e13233.	1.1	16
101	Exhaled nitric oxide and exhaled breath condensate pH as predictors of sputum cell counts in optimally treated asthmatic smokers. <i>Respirology</i> , 2011, 16, 811-818.	1.3	16
102	Serum Levels of Surfactant Proteins in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE). <i>PLoS ONE</i> , 2016, 11, e0157789.	1.1	16
103	Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. <i>International Journal of COPD</i> , 2018, Volume 13, 1229-1237.	0.9	16
104	Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature. <i>European Respiratory Review</i> , 2021, 30, 200115.	3.0	16
105	Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING). <i>International Journal of COPD</i> , 2016, Volume 11, 1425-1434.	0.9	15
106	Smoking asthma phenotype. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 53-58.	1.2	15
107	Prediction and prevention of exacerbations and mortality in patients with COPD. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 739-753.	1.0	15
108	Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. <i>Respiratory Research</i> , 2019, 20, 4.	1.4	15

#	ARTICLE	IF	CITATIONS
109	Occlusion of the upper airway does not augment the cardiovascular response to arousal from sleep in humans. <i>Journal of Applied Physiology</i> , 2005, 98, 1349-1355.	1.2	14
110	Levels of angiotensin 1 and 2 in induced sputum supernatant in patients with COPD. <i>Cytokine</i> , 2012, 58, 455-460.	1.4	14
111	Prediction of Hospitalization Stay in COPD Exacerbations: The AECOPD-F Score. <i>Respiratory Care</i> , 2014, 59, 1679-1686.	0.8	14
112	Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 635-640.	0.7	14
113	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. <i>International Journal of COPD</i> , 2018, Volume 13, 1125-1134.	0.9	14
114	Reduction in Hospitalizations for Respiratory Diseases during the First COVID-19 Wave in Greece. <i>Respiration</i> , 2021, 100, 588-593.	1.2	14
115	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. <i>ERJ Open Research</i> , 2020, 6, 00193-2020.	1.1	14
116	Residual Pleural Thickening Is Related to Vascular Endothelial Growth Factor Levels in Parapneumonic Pleural Effusions. <i>Respiration</i> , 2010, 80, 472-479.	1.2	13
117	Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis. <i>Respirology</i> , 2020, 25, 393-400.	1.3	13
118	Vascular Endothelial Growth Factor Levels in Pleural Fluid and Serum of Patients With Tuberculous Pleural Effusions. <i>Chest</i> , 2005, 128, 468.	0.4	12
119	Non-invasive ventilation in chronic hypercapnic COPD patients with exacerbation and a pH of 7.35 or higher. <i>European Journal of Internal Medicine</i> , 2007, 18, 524-530.	1.0	12
120	Serum Angiotensin-2 and CRP Levels During COPD Exacerbations. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 46-51.	0.7	12
121	Matrix Metalloproteinase Levels in the Differentiation of Parapneumonic Pleural Effusions. <i>Respiration</i> , 2010, 80, 285-291.	1.2	11
122	Predictors of future exacerbation risk in patients with asthma. <i>Postgraduate Medicine</i> , 2016, 128, 687-692.	0.9	11
123	Serum periostin in patients hospitalized for COPD exacerbations. <i>Cytokine</i> , 2017, 93, 51-56.	1.4	11
124	Prevalence and determinants of current cigarette smoking and secondhand smoking among Greek adolescents: the Global Youth Tobacco Survey (GYTS) 2013 study. <i>BMJ Open</i> , 2020, 10, e034760.	0.8	11
125	Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database. <i>International Journal of COPD</i> , 2020, Volume 15, 1729-1738.	0.9	11
126	Corticosteroids in COVID-19: one size does not fit all. <i>European Respiratory Journal</i> , 2021, 57, 2100224.	3.1	11

#	ARTICLE	IF	CITATIONS
127	Anti-Interleukin-5 Therapy and Severe Asthma. <i>New England Journal of Medicine</i> , 2009, 360, 2576-2578.	13.9	10
128	Levels of prostaglandin E2 and Cysteinyl-leukotrienes in sputum supernatant of patients with asthma: The effect of smoking. <i>Clinical and Experimental Allergy</i> , 2012, 43, n/a-n/a.	1.4	10
129	Angiopietins 1 and 2 in sputum supernatant of optimally treated asthmatics: the effect of smoking. <i>European Journal of Clinical Investigation</i> , 2015, 45, 56-62.	1.7	10
130	RELIGHT: A two-year REAL-life study of mepolizumab in patients with severe eosinophilic asthma in Greece: Evaluating the multiple components of response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2848-2852.	2.7	10
131	Diagnostic accuracy of biomarkers of oxidative stress in parapneumonic pleural effusions. <i>European Journal of Clinical Investigation</i> , 2011, 41, 349-356.	1.7	9
132	Respiratory tract mortality in cement workers: a proportionate mortality study. <i>BMC Pulmonary Medicine</i> , 2012, 12, 30.	0.8	9
133	"Education is the passport to the future": enabling today's medical teachers to prepare tomorrow's respiratory health practitioners. <i>European Respiratory Journal</i> , 2014, 44, 578-584.	3.1	9
134	e-Learning for the medical team: the present and future of ERS Learning Resources. <i>Breathe</i> , 2014, 10, 296-304.	0.6	9
135	Does the Term "Deflators" Reflect More Accurately the Beneficial Effects of Long-acting Bronchodilators in COPD?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 537-539.	0.7	9
136	Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation. <i>Lung</i> , 2018, 196, 201-205.	1.4	9
137	COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population. <i>Thorax</i> , 2020, 75, 351-353.	2.7	9
138	Prothrombotic state in patients with stable COPD: an observational study. <i>ERJ Open Research</i> , 2021, 7, 00297-2021.	1.1	9
139	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , 2021, Volume 16, 2301-2322.	0.9	9
140	Alveolar adenoma: an extremely rare innocent coin lesion. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2012, 14, 335-337.	0.5	8
141	Exposure to secondhand smoke promotes sympathetic activity and cardiac muscle cachexia. <i>International Journal of Environmental Health Research</i> , 2014, 24, 189-194.	1.3	8
142	Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?. <i>Journal of Thoracic Disease</i> , 2018, 10, 740-748.	0.6	8
143	Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study. <i>Respiratory Research</i> , 2020, 21, 93.	1.4	8
144	Classification of COPD patients and compliance to recommended treatment in Greece according to GOLD 2017 report: the RELICO study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 216.	0.8	8

#	ARTICLE	IF	CITATIONS
145	Activin A and follistatin in patients with asthma. Does severity make the difference?. <i>Respirology</i> , 2017, 22, 473-479.	1.3	7
146	Microbiota and asthma: Clinical implications. <i>Respiratory Medicine</i> , 2019, 146, 28-35.	1.3	7
147	Collateral Damage: Depressive Symptoms in the Partners of COPD Patients. <i>Lung</i> , 2014, 192, 519-524.	1.4	6
148	Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 185-191.	0.7	6
149	Exhaled breath temperature in optimally treated asthmatics: severity and underlying mechanisms. <i>Journal of Breath Research</i> , 2018, 12, 026013.	1.5	6
150	Prevalence of lung function impairment among Greek cement production workers: a cross-sectional study. <i>Industrial Health</i> , 2018, 56, 49-52.	0.4	6
151	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 43-51.	2.5	6
152	Blood eosinophils as predictor of outcomes in patients hospitalized for COPD exacerbations: a prospective observational study. <i>Biomarkers</i> , 2021, 26, 354-362.	0.9	6
153	Primary care and COVID-19: cutting the Gordian knot – the Greek experience and algorithm. <i>ERJ Open Research</i> , 2020, 6, 00468-2020.	1.1	6
154	Self-perceived quality of sleep among COPD patients in Greece: the SLEPICO study. <i>Scientific Reports</i> , 2022, 12, 540.	1.6	6
155	Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial. <i>Respiratory Research</i> , 2022, 23, 26.	1.4	6
156	Bilious pericardial effusion at initial presentation in a patient with lung cancer. <i>World Journal of Surgical Oncology</i> , 2003, 1, 24.	0.8	5
157	Airway and systemic eosinophilia in asthma: does site matter?. <i>European Respiratory Journal</i> , 2014, 44, 14-16.	3.1	5
158	Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD – a randomised controlled study. <i>Respiratory Research</i> , 2017, 18, 13.	1.4	5
159	Serum uric acid and arterial lactate levels in patients with obstructive sleep apnea syndrome: the effect of CPAP treatment. <i>Postgraduate Medicine</i> , 2021, 133, 518-524.	0.9	5
160	Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. <i>Journal of Pragmatic and Observational Research</i> , 2021, Volume 12, 25-35.	1.1	5
161	Autoimmunity and Chronic Obstructive Pulmonary Disease: Thinking beyond Cigarette Smoke. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1248-1249.	2.5	4
162	Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 111-116.	1.1	4

#	ARTICLE	IF	CITATIONS
163	Diagnostic accuracy of T2 biomarkers for the prediction of airway eosinophilia in treated smoking asthmatic patients with loss of asthma control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 385-387.e2.	2.0	4
164	The Role of Digital Tools in the Timely Diagnosis and Prevention of Acute Exacerbations of COPD: A Comprehensive Review of the Literature. <i>Diagnostics</i> , 2022, 12, 269.	1.3	4
165	BMI and Gastroesophageal Reflux in Women. <i>New England Journal of Medicine</i> , 2006, 355, 848-850.	13.9	3
166	Editorial [Hot Topic: Non-Invasive Assessment of Asthmatic Inflammation: From Bench to Bedside (Guest Editors: S. Loukides, K. Kostikas and P. Bakakos)]. <i>Current Medicinal Chemistry</i> , 2011, 18, 1413-1414.	1.2	3
167	Noninvasive evaluation of airway inflammation in patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 316-321.	0.5	3
168	Changes in BODE Quartiles After Pulmonary Rehabilitation Do Not Predict 2-Year Survival in Patients With COPD. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2016, 36, 62-67.	1.2	3
169	The association between serum periostin and a type 2 helper airway composite index in optimally treated asthmatics. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1129-1131.e3.	2.0	3
170	<p>Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1831-1838.	0.9	3
171	<p>A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 515-526.	0.9	3
172	<p>Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study</p>. <i>Journal of Pragmatic and Observational Research</i> , 2020, Volume 11, 55-66.	1.1	3
173	The Perception of Physicians on Gender-Specific Differences in the Diagnosis of COPD: Results from a Questionnaire-Based Survey. <i>International Journal of COPD</i> , 2021, Volume 16, 901-907.	0.9	3
174	Artificial intelligence in COPD: Possible applications and future prospects. <i>Respirology</i> , 2021, 26, 641-642.	1.3	3
175	Efficacy of indacaterol/glycopyrronium <i>versus</i> salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials. <i>ERJ Open Research</i> , 2021, 7, 00816-2020.	1.1	3
176	CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. <i>Patient Related Outcome Measures</i> , 0, Volume 13, 53-68.	0.7	3
177	Reducing Tolerance for SABA and OCS towards the Extreme Ends of Asthma Severity. <i>Journal of Personalized Medicine</i> , 2022, 12, 504.	1.1	3
178	The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?. <i>ERJ Open Research</i> , 2022, 8, 00065-2022.	1.1	3
179	Isocapnic Cold Air Challenge in Patients with COPD: Are There any Predisposing Factors?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008, 5, 171-176.	0.7	2
180	Duration of Hospitalization and Lung Function Deterioration as Predictors of Future Chronic Obstructive Pulmonary Disease Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 698-700.	2.5	2

#	ARTICLE	IF	CITATIONS
181	Superior vena cava syndrome due to isolated intrapulmonary Castleman's disease. <i>Asian Cardiovascular and Thoracic Annals</i> , 2017, 25, 244-245.	0.2	2
182	Revisiting IL-13 blockade: can we reach the wonderland the inhaled way?. <i>EBioMedicine</i> , 2018, 35, 6-7.	2.7	2
183	Inflammatory profile in optimally treated patients with adult versus early-onset asthma. <i>Postgraduate Medicine</i> , 2019, 131, 324-329.	0.9	2
184	Is it prime time to consider a clinical trial of doxycycline for the management of COVID-19?. <i>Postgraduate Medical Journal</i> , 2022, 98, e107-e107.	0.9	2
185	Letter from Greece. <i>Respirology</i> , 2021, 26, 715-717.	1.3	2
186	The Role of Blood Eosinophils in the Management of COPD: An Attempt to Answer the Important Clinical Questions. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 690-699.	0.7	2
187	The Diagnostic Role of Uric Acid to Creatinine Ratio for the Identification of Patients with Adverse Pulmonary Embolism Outcomes. <i>Diagnostics</i> , 2022, 12, 193.	1.3	2
188	Real-life effectiveness of ICS/LABA inhalers in asthma: The evidence generated and future needs for optimal patient management. <i>Pneumon</i> , 2021, , 1-3.	0.6	2
189	The present and future of inhalation therapy for the management of obstructive airway diseases: Emphasis on pressurized metered-dose inhalers. <i>Pneumon</i> , 2021, , 1-13.	0.6	2
190	Baseline characteristics and outcome predictors in patients hospitalized with COVID-19 in the University General Hospital of Ioannina, Greece. <i>Pneumon</i> , 2022, 35, 1-10.	0.6	2
191	Right Aortic Arch With an Aberrant Left Subclavian Artery Causing Tracheoesophageal Compression. <i>Journal of Bronchology</i> , 2004, 11, 266-267.	0.2	1
192	Amyloid cardiomyopathy presenting as persistent symptomatic pleural effusions. <i>Respiratory Medicine Extra</i> , 2005, 1, 79-80.	0.1	1
193	Tuberculous disseminated lymphadenopathy in an immunocompetent non-HIV patient: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 9316.	0.4	1
194	Biomarkers in COPD: Is Mortality the Holy Grail?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 557-559.	0.7	1
195	Tailored treatment of sleep disordered breathing in patients with chronic heart failure improves cardiac function. <i>International Journal of Cardiology</i> , 2013, 168, 4529.	0.8	1
196	Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 390-392.	2.5	1
197	Outpatient Management of COVID-19 Disease: A Holistic Patient-Centered Proposal Based on the Greek Experience. <i>Journal of Personalized Medicine</i> , 2021, 11, 709.	1.1	1
198	Early Clinically Important Improvement (ECII) and exacerbation outcomes in the FLAME study. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
199	Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study. , 2018, , .		1
200	Eosinophils and acute exacerbation of COPD: a potent biomarker for patients at increased risk. Preliminary reports. , 2018, , .		1
201	Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes. , 2018, , .		1
202	Late Breaking Abstract - Blood Eosinophils as Predictor of Outcomes in hospitalized COPD Exacerbations: Results from a Prospective Study. , 2019, , .		1
203	Using simple blood count for the diagnosis of pulmonary embolism in chronic obstructive pulmonary disease exacerbations: are we there yet?. Polish Archives of Internal Medicine, 2018, 128, 7-8.	0.3	1
204	Validation study of the portable Air Next spirometer: preliminary results. , 2019, , .		1
205	Evaluating the Impact of Triple Therapy on Mortality in Copd: The End is the Beginning?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2022, 19, 57-60.	0.7	1
206	Microalbuminuria on admission for acute exacerbation of COPD as a predictor of all-cause mortality and future exacerbations. Postgraduate Medical Journal, 2023, 99, 189-197.	0.9	1
207	Response to "Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer". Lung Cancer, 2009, 65, 254-255.	0.9	0
208	"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD. BMC Pulmonary Medicine, 2010, 10, 48.	0.8	0
209	Editorial (Hot Topic: COPD Management Beyond Bronchodilation: Current Targets and Future) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.0	0
210	Quantitative computed tomography: what does airway obstruction look-like?. Journal of Thoracic Disease, 2016, 8, E1044-E1046.	0.6	0
211	25-hydroxyvitamin D in malignant pleural disease: a prospective cohort study. Clinical Respiratory Journal, 2018, 12, 467-473.	0.6	0
212	Asthma and chronic obstructive pulmonary disease overlap: Diagnostic stability and inflammatory characteristics. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2271-2273.	2.7	0
213	Letter from Greece. Respirology, 2019, 24, 700-701.	1.3	0
214	A 68-year-old man with haemoptysis and extensive ipsilateral lung infiltrates. Breathe, 2021, 17, 200229.	0.6	0
215	Pneumon in 2021: Entering a new e-Era. Pneumon, 2021, , 1-2.	0.6	0
216	Biomarkers in Chronic Obstructive Pulmonary Disease (COPD): Current Concerns and Future Prospects. , 2014, , 1-25.		0

#	ARTICLE	IF	CITATIONS
217	Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus salmeterol/fluticasone (SFC): the FLAME study. , 2017, , .		0
218	Basal membrane biomarkers in stable and exacerbated COPD. , 2017, , .		0
219	Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study. , 2017, , .		0
220	Hyaluronic acid, heparan sulfate and chondroitin sulfate are altered during exacerbations of COPD. , 2017, , .		0
221	Irisin is associated with clinical outcomes and up-regulated by long-acting anticholinergics in COPD. , 2017, , .		0
222	Early changes in eDiary COPD symptoms predict trough FEV1 and TDI responders at 12 weeks in the CRYSTAL trial. , 2017, , .		0
223	Emphysematous phenotype is characterized by low eosinophils - a cross-sectional study. , 2017, , .		0
224	Th2 related biomarkers as predictors of airway eosinophilia in optimally treated smoking asthmatics: An observational study. , 2017, , .		0
225	Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study. , 2017, , .		0
226	Characterisation of UK and US COPD populations in reference to exacerbation frequency and blood eosinophils level. , 2018, , .		0
227	Impact of stable state symptoms on the future burden of COPD exacerbations. , 2018, , .		0
228	Dual bronchodilation vs triple therapy in the real-life DACCORD study. , 2018, , .		0
229	The effects of pulmonary rehabilitation in patients with Combined Pulmonary Fibrosis and Emphysema (CPFE). , 2018, , .		0
230	Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial. , 2018, , .		0
231	Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis. , 2018, , .		0
232	Glycated hemoglobin (HbA1c) and acute exacerbation in chronic obstructive pulmonary disease: a potent biomarker of severity and prognosis. Preliminary data.. , 2018, , .		0
233	Disease control and treatment pathways of asthma patients after initiating ICS/LABA. , 2018, , .		0
234	Late Breaking Abstract - Characteristics and treatment of patients with comorbid COPD and heart failure. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
235	Baseline symptom burden and dual bronchodilator response in the FLAME study. , 2018, , .		0
236	Indacaterol/glycopyrronium increases lung ventilation in COPD patients as measured by hyperpolarized 3He MRI. , 2018, , .		0
237	Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials. , 2018, , .		0
238	Population health impact of Indacaterol/Glycopyrronium over 4 years in chronic obstructive pulmonary disease. , 2018, , .		0
239	Late onset asthma: A distinct phenotype. , 2018, , .		0
240	Small airways disease evaluation in patients with mild/moderate asthma and correlation with bronchial hyperresponsiveness and disease control. , 2018, , .		0
241	Dual bronchodilator response according to bronchitis symptoms in the FLAME study. , 2018, , .		0
242	Extracellular matrix glycosaminoglycans can predict severity and outcome in COPD. , 2018, , .		0
243	PP128 Quantifying The Relative Importance Of Chronic Obstructive Pulmonary Disease Symptoms To Patients. International Journal of Technology Assessment in Health Care, 2019, 35, 61-61.	0.2	0
244	Health care resource utilization (HCRU) in early and late diagnosed Chronic Obstructive Pulmonary Disease (COPD) patients in UK primary care. , 2019, , .		0
245	Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies. , 2019, , .		0
246	Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment. , 2019, , .		0
247	Pulmonary hypertension in COPD patients: a systematic review and meta-analysis. , 2019, , .		0
248	Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients. , 2019, , .		0
249	Fractionated exhaled nitric oxide in COPD patients. , 2019, , .		0
250	Clinical consequences of late Chronic Obstructive Pulmonary Disease (COPD) diagnosis compared to early diagnosis in UK primary care. , 2019, , .		0
251	Evaluation of the Clinical Effectiveness of the Salmeterol/Fluticasone Fixed-Dose Combination Delivered via the Elpenhaler® Device in Greek Patients with Chronic Obstructive Pulmonary Disease and Comorbidities: The AEOLUS Study. Journal of Personalized Medicine, 2021, 11, 1159.	1.1	0
252	Reply. Respiriology, 2022, , .	1.3	0

#	ARTICLE	IF	CITATIONS
253	Die Rolle digitaler Hilfsmittel bei der rechtzeitigen Diagnose und Vorbeugung akuter Exazerbationen der COPD: Ein umfassender Überblick über die Literatur. Karger Kompass Pneumologie, 0, , 1-10.	0.0	0